Literature DB >> 1455304

Occult functioning insulinomas: which localizing studies are indicated?

J A van Heerden1, C S Grant, P F Czako, F J Service, J W Charboneau.   

Abstract

BACKGROUND: An occult insulinoma refers to a biochemically proven tumor with an anatomic site that remains indeterminate before operation. The amount of radiologic localization for such patients is debatable.
METHODS: Sixty-five patients with sporadic insulinomas were surgically treated at the Mayo Clinic between January 1980 and December 1990. True occult tumors were present in 31% of these patients (n = 20). Thirty-eight negative preoperative localization studies were performed, with 10 patients undergoing more than one study. A benign adenoma was found in 19 patients when they underwent exploratory operation, whereas one patient had malignant disease with hepatic metastases. Thirteen patients underwent intraoperative ultrasonography with a 7.5 MHz real-time high-resolution transducer.
RESULTS: Solitary lesions were successfully removed either by enucleation or by distal pancreatectomy in all 19 patients with benign disease.
CONCLUSIONS: This high success rate in the management of occult insulinomas suggests that extensive preoperative radiologic investigation is neither indicated nor cost-effective.

Entities:  

Mesh:

Year:  1992        PMID: 1455304

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  16 in total

1.  Insulinoma--experience from 1950 to 1995.

Authors:  M P Boukhman; J H Karam; J Shaver; A E Siperstein; Q Y Duh; O H Clark
Journal:  West J Med       Date:  1998-08

2.  Laparoscopic surgery in patients with sporadic and multiple insulinomas associated with multiple endocrine neoplasia type 1.

Authors:  Laureano Fernández-Cruz; Isidro Martínez; Gleydson Cesar-Borges; Emiliano Astudillo; David Orduña; Irene Halperin; Gemma Sesmilo; Manuel Puig
Journal:  J Gastrointest Surg       Date:  2005-03       Impact factor: 3.452

3.  Laparoscopic ultrasound enhances standard laparoscopy in the staging of pancreatic cancer.

Authors:  E A Minnard; K C Conlon; A Hoos; E C Dougherty; L E Hann; M F Brennan
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

Review 4.  Morphological and functional investigations of neuroendocrine tumors of the pancreas.

Authors:  Philippe L Pereira; Jakub Wiskirchen
Journal:  Eur Radiol       Date:  2003-05-06       Impact factor: 5.315

5.  Accurate preoperative localization of insulinomas avoids the need for blind resection and reoperation: analysis of a single institution experience with 17 surgically treated tumors over 19 years.

Authors:  Brian K P Goh; London L P J Ooi; Peng-Chung Cheow; Yu-Meng Tan; Hock-Soo Ong; Yaw-Fui A Chung; Pierce K H Chow; Wai-Keong Wong; Khee-Chee Soo
Journal:  J Gastrointest Surg       Date:  2009-03-17       Impact factor: 3.452

6.  Response of human insulinoma cells to extracellular calcium is different from normal B cells.

Authors:  M Kato; R Doi; M Imamura; N Okada; Y Shimada; R Hosotani; J I Miyazaki
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

Review 7.  Occult sporadic insulinoma: localization and surgical strategy.

Authors:  Bassam Abboud; Joe Boujaoude
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

8.  Surgical approach to insulinomas: are pre-operative localisation tests necessary?

Authors:  K Ravi; B J Britton
Journal:  Ann R Coll Surg Engl       Date:  2007-04       Impact factor: 1.891

9.  Carcinoma of the pancreatic head and periampullary region. Tumor staging with laparoscopy and laparoscopic ultrasonography.

Authors:  T G John; J D Greig; D C Carter; O J Garden
Journal:  Ann Surg       Date:  1995-02       Impact factor: 12.969

10.  Selective intra-arterial calcium stimulation with hepatic venous sampling for preoperative localization of insulinomas.

Authors:  Yon Mi Sung; Young Soo Do; Moon-Kyu Lee; Sung Wook Shin; Wei Chiang Liu; Sung Wook Choo; In-Wook Choo
Journal:  Korean J Radiol       Date:  2003 Apr-Jun       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.